Neovacs SA (FR:ALNEV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neovacs SA has announced a €0.2 million capital increase through the issuance of OCEANE-BSA securities, with the funds aimed at financing their Kinoïde® allergy research program and other promising Biotech and Medtech projects. This operation has already raised €24.7 million, resulting in significant share dilution, and the latest issuance could lead to the creation of additional new shares. Investors are warned of potential risks including market pressure on share prices and the dilutive impact of these financing operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.